Get started
ELI LILLY AND COMPANYELI LILLY AND COMPANYELI LILLY AND COMPANY

ELI LILLY AND COMPANY

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

LLY trade ideas

LLY: On The Brink Of CollapseEli Lilly is the one stock I've made the most returns on this year. With it's violent up and down swings, it's exactly what you look for as an options trader. As I've been observing LLY over the last few weeks, I decided to go back in time again to the origins of this monstrous parabolic move and share it with you all. If you look at the smaller time frames, you will see that LLY has filled it's gap target to the upside, but there are so many gaps to the downside. When the market does decide to fall hard, I believe LLY will fall the hardest. Is this not the perfect stock to fit the old adage, "THE BIGGER THEY ARE, THE HARDER THEY FALL?" Once LLY breaks below 747, the next targets are well below the current price. This means BIG returns for options traders. I don't see much more upside for this stock (if any), so the downside potential will play favorably. PT1 747 PT2 609 Targets are 1 to 2 months.
NYSE:LLYShort
by FiboTrader1
1
Eli Lilly Shares Surge Over 9% After Strong Earnings ReportEli Lilly Shares Surge Over 9% After Strong Earnings Report As the chart of Eli Lilly's (LLY) share price shows today, yesterday's trading closed at a level more than 9% higher than Wednesday's closing price. The main driver of this growth was a strong Q2 report: → Earnings per share: actual = $3.92, expected = $2.74; → Gross sales: actual = $11.3 billion, expected = $9.99 billion. Market participants reacted positively not only to the fact that the American pharmaceutical company's actual results significantly exceeded forecasts but also to Eli Lilly's rising expectations for the second half of the year, driven by demand for its diabetes treatment Mounjaro and weight loss drug Zepbound. Technical analysis of the Eli Lilly (LLY) stock chart shows that: → The price action is forming an upward channel in 2024 (shown in blue); → After a rebound, the median line of this channel was breached (as indicated by the arrow); → As could be expected, this line acted as resistance – as indicated by the high of yesterday's candlestick. What is the forecast for Eli Lilly (LLY) shares? Wall Street analysts surveyed by TipRanks remain positive – none of them recommend selling shares of the company, which has the largest market cap in the healthcare sector at over $800 billion. On average, they forecast that LLY shares will reach $955 within 12 months. This suggests that the current upward channel may remain relevant. However, it’s possible that: → The lower boundary will continue to act as support; → The boundaries of the bullish gap formed at yesterday's opening may also provide support. A similar action can be seen on the chart – after a wide bullish gap (also formed following a strong report) on 30 April, LLY shares found support near the lower boundary of that gap around $740. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:LLY
by FXOpen
2
Eli Lilly Surges 12% On Strong Earnings Beat and Q2 ReportsEli Lilly & Co. (NYSE: NYSE:LLY ) has once again captured the spotlight with its impressive second-quarter performance in 2024. The pharmaceutical giant’s stock surged by over 12% following the announcement of its quarterly earnings, driven largely by the soaring sales of its diabetes drug Mounjaro and weight loss injection Zepbound. Blowing Past Expectations Eli Lilly reported $11.3 billion in revenue and $2.97 billion in net profit for Q2, far exceeding Wall Street’s expectations. Analysts had anticipated $9.97 billion in revenue and $2.48 billion in profit, according to FactSet. The company also reported earnings per share (EPS) of $3.28, significantly higher than the $2.74 forecasted by analysts. This remarkable performance marks a 36% increase in revenue and a staggering 68% increase in profit compared to the same period last year. In Q2 2023, Lilly had reported $8.31 billion in sales and $1.76 billion in profit. The pharmaceutical giant’s strong earnings prompted a bullish revision of its full-year guidance. Eli Lilly raised its forecasted EPS for the year to between $16.10 and $16.60, up from its previous guidance of $13.50 to $14 per share. Additionally, the company now expects annual revenue to range between $45.4 billion and $46.6 billion, an increase of $3 billion at both ends of the range. Mounjaro and Zepbound: The Driving Forces The extraordinary demand for Lilly’s diabetes and weight loss drugs, Mounjaro and Zepbound, has been the primary catalyst for its Q2 success. Mounjaro, which generated $3.09 billion in revenue during the quarter, saw its sales more than triple from the same period last year. Zepbound, a relatively new entrant to the market, raked in $1.24 billion in sales, far surpassing the $922.2 million that analysts had projected. The growth in Mounjaro and Zepbound’s sales comes amidst a broader surge in the weight loss drug market, which some analysts estimate could reach $130 billion by the end of the decade. Eli Lilly, along with Danish competitor Novo Nordisk, has established a near-duopoly in this space, though the field is rapidly attracting interest from other pharmaceutical giants and startups. Navigating Supply Challenges The extraordinary demand for Mounjaro and Zepbound has led to supply constraints, a challenge that Eli Lilly has been aggressively addressing. The company has invested heavily in expanding its manufacturing capabilities, including building six new plants and hiring thousands of workers. The recent easing of supply issues for both drugs in the U.S. is a testament to these efforts. Eli Lilly’s CEO, David Ricks, expressed confidence in the company’s ability to meet the growing demand for its products. “We just see unbelievable demand, and we’re not even trying that hard to market this drug,” Ricks told CNBC. He added that the company’s supply chain improvements have been crucial in driving the quarter’s success. Future Outlook: Beyond Weight Loss Eli Lilly is not resting on its laurels. The company is actively working to expand its dominance in the weight loss drug market by developing new treatments and exploring additional uses for its existing drugs. Two promising candidates are in late-stage clinical trials: orfoglipron, an oral weight loss pill, and retatrutide, a hormone-mimicking injection. Results for orfoglipron are expected next year, while retatrutide’s results are anticipated in 2026. Furthermore, Lilly is exploring new indications for its drugs, such as using Zepbound to treat sleep apnea. If successful, this could further bolster Lilly’s market position and open new revenue streams. Market Reaction and Investor Confidence Eli Lilly’s robust earnings report and optimistic outlook have led to a surge in investor confidence. The company’s shares jumped 10% during premarket trading following the earnings announcement, and they have continued to climb, reflecting the market’s positive reception. With a market capitalization of over $730 billion, Eli Lilly (NYSE: NYSE:LLY ) is now the largest pharmaceutical company in the U.S. The company’s stock has risen more than 30% this year, building on a nearly 60% increase in 2023. This growth underscores investor confidence in the long-term potential of Lilly’s drug pipeline and its ability to navigate the challenges of a highly competitive market. Conclusion Eli Lilly’s Q2 2024 earnings report highlights the company’s strong market position and its ability to capitalize on the booming demand for diabetes and weight loss treatments. With a robust pipeline, aggressive expansion plans, and a clear focus on innovation, Eli Lilly is well-positioned to maintain its leadership in the pharmaceutical industry for years to come. As the company continues to develop new drugs and expand its market reach, investors and industry observers alike will be watching closely to see how Lilly navigates the evolving landscape.
NYSE:LLY
by DEXWireNews
Is Eli Lilly's Stock in a Bubble or just a Correction?Eli Lilly & Co. (NYSE: NYSE:LLY ) has been a standout performer in the stock market this year, with its stock price surging by around 50%, far outperforming the S&P 500’s 15% rise. This impressive performance has brought the stock to trade at 63 times its projected 2024 earnings of $13.75 per share. This raises a critical question for investors: Is Eli Lilly's stock overvalued, or is there still room for growth? Stellar Growth Driven by Innovative Drugs Eli Lilly's recent surge can be attributed primarily to the high demand for its obesity drug, Zepbound, and its diabetes drug, Mounjaro. These two drugs alone are expected to bring in $50 billion in annual peak sales. The company is currently facing a shortage of Zepbound and plans to invest $9 billion in a new manufacturing facility to meet this demand. Additionally, Eli Lilly’s pipeline is extensive, with several drugs under clinical trials across various therapeutic areas. One notable approval is Donanemab, an Alzheimer's Disease treatment, which could generate $5 billion in peak sales. Other successful drugs, such as Verzenio and Zyprexa, also contribute to the company’s robust revenue growth. Financial Performance and Future Projections Eli Lilly's revenue is projected to grow from $34 billion in 2023 to over $60 billion by 2026, representing an increase of over 75%. The company's earnings are also expected to more than triple during this period. Despite a 12% decline in net income from $6.2 billion in 2020 to $5.2 billion in 2023, mainly due to increased non-operating expenses and acquisitions, the adjusted net income margin is poised for a rebound. In Q1 2024, Eli Lilly ( NYSE:LLY ) reported an adjusted net margin of 26.6%, up over 500 basis points year-over-year. The company’s investments in R&D and product development are starting to pay off, and adjusted earnings are expected to range between $13.50 and $14.00 per share in 2024, more than double the previous year. Considering these projections and expected margin expansions, Eli Lilly’s adjusted EPS could reach $25 by 2027. If the stock price remains constant, the forward P/E multiple would decrease to 34x in 2026. However, investors are betting on the stock price increasing, resulting in a more modest P/E contraction to about 52x. This scenario would imply a 50% growth in Eli Lilly's stock price to approximately $1,300 over the next three years. Risks and Competition Despite the positive outlook, Eli Lilly faces risks, particularly from increasing competition in the obesity drug market. Competitors like Novo Nordisk, Roche, and Amgen are also making strides in weight-loss treatments. However, the obesity drugs market is projected to grow 16-fold to over $100 billion by 2030, with Eli Lilly and Novo Nordisk likely dominating this space. Is Eli Lilly's Stock in a Bubble? The term "bubble" implies a scenario where asset prices are inflated beyond their intrinsic value, often driven by speculation and a belief that prices will never fall. While Eli Lilly’s stock has seen tremendous gains, rising 656% over the past five years compared to the S&P 500’s 78.4% increase, it does not necessarily mean it is in a bubble. Eli Lilly’s rise is backed by strong fundamentals, significant revenue growth, and promising developments in its drug pipeline. Conclusion Eli Lilly’s stock is not just a result of speculative trading; it is supported by solid business performance and growth prospects. While there are competitive risks, the company’s innovative drug portfolio and strategic investments position it well for continued success. Any dip in Eli Lilly’s stock should be seen as a potential investment opportunity, offering robust long-term gains. The next few years will likely see Eli Lilly continue its upward trajectory, driven by market share gains and regulatory approvals.
NYSE:LLY
by DEXWireNews
The First Trillion Dollar Healthcare Company - Eli LillyI recently wrote about Eli Lilly and why it has caught my attention, what it may mean for markets, but more specifically the most expensive and elaborate industry on Earth, that none of us can understand... HEALTHCARE. Insurance is wildly expensive. Many people are focused on health. Scientists around the planet are trying to solve health. And now, Eli Lilly, is on the very of becoming the first trillion dollar company in healthcare. Eli Lilly is nearing $900 billion market cap and is on pace to become the first trillion dollar healthcare company. I have long followed healthcare stocks because I do believe they bring a lot of insight into health, innovation, and the natural sciences. After all, they are tasked with curing challenging diseases, sicknesses, and other aspects to help humans. Most recently, a certain stock has caught my attention. I find this to be a noteworthy development for the industry, especially while stocks like Pfizer and others, such as NASDAQ:MRNA are dropping. NYSE:PFE Place your bets accordingly. This move and alert has been added to my watchlist.
NYSE:LLY
by scheplick
Eli Lilly's Alzheimer's drug Kisunla wins FDA approvalEli Lilly & Co.'s new Alzheimer's disease drug, Kisunla, has received approval from the US Food and Drug Administration (FDA), marking a significant advancement in treating the disease. This approval positions Kisunla as the second drug available that can slow the progression of Alzheimer's, a condition affecting around 6 million Americans. Kisunla's journey to market has been fraught with regulatory hurdles, including the FDA's initial reluctance to fast-track the drug based on early trial results, preferring instead to review late-stage data. This thorough scrutiny culminated in a one-day hearing earlier this year to deliberate on Kisunla's safety and efficacy, eventually leading to its approval. Kisunla will now compete with Eisai Co.'s Leqembi, which has been available in the US since early 2023. Technical analysis of Eli Lilly & Co. (NYSE: LLY) Exploring potential trading opportunities, let us review the technical aspects of Eli Lilly's stock: Timeframe: Daily (D1) Current trend: there is an observable uptrend, though the stock has recently broken the support level at 905.00 USD and is attempting to consolidate below it Resistance level: 917.00 USD New support level: after breaking 905.00 USD, further confirmation is necessary to establish new support Potential downtrend target: if a downtrend is established, the downside target could be around 820.00 USD Short-term target: if the uptrend resumes and the stock price breaks through the resistance at 917.00 USD, a short-term target could be set at 940.00 USD Medium-term target: should the upward momentum be sustained, the price might rise to 960.00 USD Investors should closely monitor Eli Lilly’s performance, especially in light of the recent FDA approval of Kisunla. This development could significantly impact the company's market position and stock performance in the pharmaceutical sector. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:LLYLong
by RoboMarkets
ELI LILLY Entering consolidation phase. Wait for the buy signal.Last time we looked at Eli Lilly (LLY) was on March 18 (see chart below) and we got the most out of it as we entered after a 1D MA50 correction and got the most optimal value: Our original target was $1050 calculated according to the % rise of each previous Bullish Leg (+45%) of the +1 year Channel Up but now it appears that the stock won't hit that level during this Leg as we are entering the bottom phase of the Sine Wave. As you can see on the chart (now on the 1W time-frame), this is where LLY typically pulls-back and consolidates (red Rectangle) until the next Bullish Leg begins near the 1D MA100 (red trend-line). As a result, we are closing our bottom buy position and turn neutral on LLY until we approach the 1D MA100 again, starting mid-August. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
1
$LLY look out below $265 bottom coming soonNYSE:LLY looks like it's topping up here. Anytime you see a chart that has gone straight up like this, you know the fall is going to be painful. I think we'll top within the next week or two and then we're going to start the bear market that goes all the way down to $265 before it truly bounces. Why do I think this? If you create a parabola, price is starting to break through it which means we're likely to see a 80%+ correction once the trend changes. On top of this, RSI is in extreme overbought territory. If you're long, I'd set stops where you're comfortable with gains because once this move down happens, months worth of gains will evaporate.
NYSE:LLYShort
by benjihyam
2